Corbus Pharmaceuticals has appointed Rachael Brake, Ph.D., as Chief Scientific Officer.
Dr. Brake will build upon Corbus' commitment to immuno-oncology and joins the Norwood, Massachusetts-headquartered company following the recent acquisition of monoclonal antibodies that inhibit TGFβ activation.
Dr. Brake will be responsible for advancing Corbus' pipeline of TGFβ-targeting therapeutics as well as current endocannabinoid system targeting drug candidates. She will also help shape the company's broader scientific strategy to help guide future business development opportunities and refinement of the company's research scope.
Dr. Brake most recently served at Takeda Pharmaceuticals where she held multiple leadership roles in R&D, including as Vice President, Global Project Leader in Oncology. In this position, she managed a portfolio of programs and cross-functional teams responsible for the preclinical and clinical exploration of various solid tumor drug candidates spanning diverse mechanisms of action.
She is experienced in early- and late-stage clinical development, regulatory approvals (ALUNBRIG, EXKIVITY), program externalizations (DAY101, sapanisertib), and commercialization efforts.
In her most recent role as the Head, U.S. Medical Affairs, in the Oncology Business Unit, Dr. Brake developed a medical strategy for Takeda Oncology's portfolio and emerging immune-focused pipeline.
Prior to her roles at Takeda, Dr. Brake held leadership roles in Research at Amgen Inc. and Millennium Pharmaceuticals, Inc.
Dr. Brake obtained her Ph.D. in Molecular Biology and Biochemistry from the University of Western Australia Perth.